BACKGROUND AND OBJECTIVES: Understanding transmembrane transport provides a more complete understanding of the pharmacokinetics of a drug and mechanistic explanations for drug-drug interactions. Here, the transmembrane transport of danoprevir (hepatitis C virus protease inhibitor) and the effects of ritonavir and ciclosporin on transmembrane transport of danoprevir were evaluated and clinical pharmacokinetic studies of danoprevir co-administered with/without ritonavir and ciclosporin were conducted. METHODS: Transcellular transport of danoprevir was evaluated in Lewis lung cancer porcine kidney, Madin-Darby canine kidney, or Chinese hamster ovary cells transfected with human transport proteins, and in human hepatocytes. The pharmacokinetics of intravenous and oral danoprevir administered with/without ritonavir, and the impact of ciclosporin on danoprevir pharmacokinetics were evaluated in randomized, open-label, crossover studies in healthy subjects. RESULTS: Danoprevir transport in vitro involved organic anion transporting polypeptide (OATP) 1B1, OATP1B3, P-glycoprotein, and multidrug resistance protein-2, but not breast cancer resistance protein. Ritonavir and ciclosporin inhibited transport of danoprevir by human hepatocytes. The pharmacokinetics of intravenous danoprevir 6 mg were not altered by oral ritonavir 100 mg. In contrast, exposure to oral danoprevir 100 mg increased two- to threefold when co-administered with ritonavir. Absolute bioavailability of danoprevir 100 mg was low (1.15%), but increased more than threefold (3.86%) when co-administered with ritonavir. Oral ciclosporin 100 mg increased exposure to intravenous danoprevir 2 mg and oral ritonavir 100 mg. CONCLUSION: Collectively, these studies provide insight into the transmembrane transport and pharmacokinetics of danoprevir and the mechanisms that underlie a recently reported, three-way drug-drug interaction involving danoprevir, ritonavir, and ciclosporin.
BACKGROUND AND OBJECTIVES: Understanding transmembrane transport provides a more complete understanding of the pharmacokinetics of a drug and mechanistic explanations for drug-drug interactions. Here, the transmembrane transport of danoprevir (hepatitis C virus protease inhibitor) and the effects of ritonavir and ciclosporin on transmembrane transport of danoprevir were evaluated and clinical pharmacokinetic studies of danoprevir co-administered with/without ritonavir and ciclosporin were conducted. METHODS: Transcellular transport of danoprevir was evaluated in Lewis lung cancer porcine kidney, Madin-Darby canine kidney, or Chinese hamster ovary cells transfected with human transport proteins, and in human hepatocytes. The pharmacokinetics of intravenous and oral danoprevir administered with/without ritonavir, and the impact of ciclosporin on danoprevir pharmacokinetics were evaluated in randomized, open-label, crossover studies in healthy subjects. RESULTS:Danoprevir transport in vitro involved organic anion transporting polypeptide (OATP) 1B1, OATP1B3, P-glycoprotein, and multidrug resistance protein-2, but not breast cancer resistance protein. Ritonavir and ciclosporin inhibited transport of danoprevir by human hepatocytes. The pharmacokinetics of intravenous danoprevir 6 mg were not altered by oral ritonavir 100 mg. In contrast, exposure to oral danoprevir 100 mg increased two- to threefold when co-administered with ritonavir. Absolute bioavailability of danoprevir 100 mg was low (1.15%), but increased more than threefold (3.86%) when co-administered with ritonavir. Oral ciclosporin 100 mg increased exposure to intravenous danoprevir 2 mg and oral ritonavir 100 mg. CONCLUSION: Collectively, these studies provide insight into the transmembrane transport and pharmacokinetics of danoprevir and the mechanisms that underlie a recently reported, three-way drug-drug interaction involving danoprevir, ritonavir, and ciclosporin.
Authors: Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang Journal: Nat Rev Drug Discov Date: 2010-03 Impact factor: 84.694
Authors: Jordan J Feld; Ira M Jacobson; Donald M Jensen; Graham R Foster; Stanislas Pol; Edward Tam; Maciej Jablkowski; Hanna Berak; John M Vierling; Eric M Yoshida; Héctor R Perez-Gomez; Astrid Scalori; Gregory J Hooper; Jorge A Tavel; Mercidita T Navarro; Saba Shahdad; Rohit Kulkarni; Sophie Le Pogam; Isabel Nájera; Simon Eng; Chin Yin Lim; Nancy S Shulman; Ellen S Yetzer Journal: J Hepatol Date: 2014-09-18 Impact factor: 25.083
Authors: K M Hillgren; D Keppler; A A Zur; K M Giacomini; B Stieger; C E Cass; L Zhang Journal: Clin Pharmacol Ther Date: 2013-04-08 Impact factor: 6.875
Authors: Barbara J Brennan; Sebastian A Moreira; Peter N Morcos; Mercidita T Navarro; Jiney Asthappan; Petra Goelzer; Paul Weigl; Patrick F Smith Journal: Clin Pharmacokinet Date: 2013-09 Impact factor: 6.447
Authors: Stuart W Paine; Alison J Parker; Philip Gardiner; Peter J H Webborn; Robert J Riley Journal: Drug Metab Dispos Date: 2008-04-21 Impact factor: 3.922
Authors: Patrick Marcellin; Curtis Cooper; Luis Balart; Dominique Larrey; Terry Box; Eric Yoshida; Eric Lawitz; Peter Buggisch; Peter Ferenci; Martin Weltman; Emily Labriola-Tompkins; Sophie Le Pogam; Isabel Nájera; Denise Thomas; Gregory Hooper; Nancy S Shulman; Ying Zhang; Mercidita T Navarro; Chin Yin Lim; Michael Brunda; Norah A Terrault; Ellen S Yetzer Journal: Gastroenterology Date: 2013-06-26 Impact factor: 22.682
Authors: Dermot F McGinnity; George Zhang; Jane R Kenny; Geraldine A Hamilton; Sara Otmani; Karen R Stams; Suzzette Haney; Patrick Brassil; David M Stresser; Robert J Riley Journal: Drug Metab Dispos Date: 2009-03-23 Impact factor: 3.922